Article

Lenstec receives FDA clearance to begin Softec HD IOL trial

Lenstec Inc. announced that the FDA has granted the company an Investigational Device Exemption (IDE) to begin a clinical trial of the Softec HD posterior chamber IOL.

Lenstec Inc. announced that the FDA has granted the company an Investigational Device Exemption (IDE) to begin a clinical trial of the Softec HD posterior chamber IOL.

Already approved for use throughout the European Union, the Softec HD is an aberration controlled bi-aspheric IOL designed to replace the human crystalline lens following cataract removal in patients 21 years of age and older. The lens joins Lenstec's expanding Precision Series line of monofocal and accommodating IOLs.

The new U.S. clinical trial will be based on implants performed on 300 eyes. Patient enrollment will begin this month at leading vision surgery centers nationwide.

The Softec HD is inserted through a 2.5- to 3-mm clear corneal incision using standard posterior chamber IOL insertion techniques. Based on the company's proprietary manufacturing technology, Premium Series lenses are designed to improve predictability in cataract surgery by reducing the variability (i.e., tolerance or margin of error) inherent in any manufactured lens.

The lens configuration was developed to reduce variability up to 300% compared with cataract replacement lenses manufactured in accordance with ISO standards. Variability is measured as the difference between a lens' labeled prescription and its actual power. The Softec HD is available with a tolerance of just 0.125 D, and in highly precise 0.25-D increments (from +18 to +25).

For more information, visit Lenstec at Booth 3638.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.